1

HALAMAN PENGESAHAN

1.

Judul Kegiatan

Analisis Potensi Madu Apis mallifera sebagai pendekatan preventif komplikasi vaskuler
pada pasien DM tipe II: Sebuah Upaya Pembuktian QS. An-Nahl 68-69 melalui Kajian
Biokimiawi.
2. Ketua Pelaksana Kegiatan
a. Nama Kelompok
: Gamal
b. NIM
: 0710713014
c. Jurusan
: Fakultas Kedokteran
d. Universitas/Institut/Politeknik
: Brawijaya
e. Alamat Rumah dan No Tel./HP : Jl. Ahmad Yani 129 Malang
f.
Alamat email
: dr_helper77@yahoo.com
4. Anggota Pelaksana Kegiatan/Penulis : orang
5. Dosen Pendamping:
a. Nama Lengkap dan Gelar
: Dr. dr. Nurdiana, M.Kes
b. NIP
: 19551015 198603 2 001

Malang, 24 Maret 2010

Ketua Pelaksana

Gamal
NIM. 0710713014

Pembantu Dekan III

Dosen Pembimbing

Fakultas Kedokteran Brawijaya

dr. M. Hanafi, MPH

Dr. dr. Nurdiana, M.Kes

NIP. 19490925 198003 1 001

NIP. 19551015 198603 2 001

KATA PENGANTAR
Puji syukur kepada Tuhan Yang Maha Esa karena atas rahmat-Nya penulis dapat
menyelesaikan karya tulis yang berjudul Analisis Potensi Madu Apis mallifera sebagai
pendekatan preventif komplikasi vaskuler pada pasien DM tipe II: Sebuah Upaya Pembuktian
QS. An-Nahl 68-69 melalui Kajian Biokimiawi..
Penulis mengucapkan terima kasih kepada:
1. Dr. dr. Nurdiana, M.Kes selaku dosen pembimbing yang bersedia menuntun penulis dalam
penyusunan karya tulis ini,
2.
Dr. dr. Samsul Islam, SpMK, M.Kes selaku Dekan yang senantiasa
mendukung penulis dalam penulisan proposal penelitian ini, dan
3.
semua pihak yang telah ikut berperan aktif demi terselesaikannya
penulisan proposal penelitian ini.
Hasil analisis ini diharapkan dapat dimanfaatkan sebagai dasar penelitian selanjutnya
dalam memanfaatkan madu Apis Mallifera dan dapat mencari obat diabetes mellitus yang efektif,
alamiah, dan relatif terjangkau, karena pengobatan diabetes mellitus mempunyai life time
medication. Analisis ini diharapkan dapat menjadi inovasi baru dalam pemanfaatan madu Apis
Mellifera dan dapat dikembangkan sebagai obat alternatif diabetes mellitus. Disamping itu
pembuatan karya tulis ini diharapkan mampu membuktikan kebenaran ayat suci Al-Quran.
Penulis menyadari bahwa karya tulis ini belumlah sempurna dan masih banyak kesalahan
yang terjadi. Penulis mengharapkan saran dan masukan dari para pembaca demi penyempurnaan
karya tulis ini selanjutnya.
Malang, 24 Maret 2010

Penulis

DAFTAR ISI
Lembar Pengesahan

Kata Pengantar

ii

Daftar Isi

iii

Daftar Tabel

iv

Daftar Gambar

Daftar Lampiran

vi

Bab I. Pendahuluan
1.1.
1.2.
1.3.
1.4.

Latar Belakang
Rumusan masalah
Tujuan Penulisan
Manfaat Penulisan

Bab II. Telaah Pustaka

1
3
3
4

2.1.

Diabetes Mellitus

2.2.

Resistensi Insulin DM tipe II

2.3

Advanced Glycation End Products (AGEs)

2.3.

Reactive Oxygen Species (ROS)

2.4.

Nuclear Factor-kappa B (NF-B)

10

2.6.

Antioksidan

12

2.7

Quercetin

14

2.8

Madu Apis Mallifera

15

Bab III. Isi

3.1.

Ketidakseimbangan Oksidan dan Antioksidan Akibat Hiperglikemi pada DMT2

3.2.

Komplikasi Vaskuler Sebagai Akibat Ketidakseimbangan Oksidan dan Antioksidan

20
23

pada DMT2
3.3.

Mekanisme Kerja Quercetin dalam Benalu Randu dalam Menghambat Komplikasi

24

Vaskuler pada DMT2

3.4

Analisis Strategis Implementasi Madu Apis malifera Sebagai komplikasi Vaskuler

24

pasien DMT2
3.5

Analisis QS. An-Nahl ayat 69 melalui pendekatan biokimiawi

27

3.6

Kesimpulan dan saran

28
29

4
Daftar Pustaka
Lampiran

viii
xvii

DAFTAR TABEL

Tabel 1

Gen yang diregulasi oleh NF-kB

14

Tabel 2

Klasifikasi dan sumber utama flavonoid

15

Tabel 3

Kadar Quercetin pada beberapa makanan

18

Tabel 4

Pengaruh pemberian Quercetin pada kultur HUVECs diinduksi

19

Hiperleptin

DAFTAR GAMBAR

Gambar 1

Aktivator dari jalur IKK/NF-kB menghambat signal insulin.

Gambar 2

Formasi pembentukan AGEs

10

Gambar 3

Mekanisme peningkatan stress oksidatif pada DM

11

Gambar 4

Jalur Akivasi NF-kB

13

Gambar 5

Struktur Kimia Quercetin

17

Gambar 6

Madu Apis Mallifera

20

Gambar 7

Usulan analisis potensi quercetin pada DMT2

26

DAFTAR LAMPIRAN
Lampiran 1

Nama dan Biodata Kelompok

xvii

Daftar Pustaka
Al-Quran Al-Karim
Suyono, Slamet. (2007). Patofisiologi Diabetes Melitus dalam Penatalaksanaan Diabetes
Melitus Terpadu. Jakarta: Pusat Diabetes dan Lipid RSUP Nasional Dr. Cipto
Mangunkusumo, Fakultas Kedokteran Universitas Indonesia.
Yusharmen, I Nyoman Kandun, Hariadi Wibisono, Endang R Sedyaningsih, Widarso. 2005. New
England Journal of Medicine, 355(21) : 2186-94.
WHO. 2008. Diabetes. (Online) (http://www.who.int/diabetes/facts/ world_figures/en/, diakses
25 September 2009)
Mansjoer, Arif. 2007. Kapita Selekta Kedokteran. Edisi Ketiga. Jakarta: Media Aesculapius.
Price, S.A. and Wilson, L.M. 2006. Patofisiologi : Konsep Klinis Proses-proses Penyakit
(Volume 2 Edisi 6). Jakarta : EGC.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology,
pathophysiology, and management. JAMA, 287:2570-81, 2002
Gutterman D. Vascular dysfunction in hyperglycemia. Is Protein Kinase-C the culprit. Circ Res.
90:5-7, 2002
Ahmed, S., E. Nawata, M. Hosokawa, Y. Domae, and T. Sakuratani. 2002. Alterations in
photosynthesis and some antioxidant enzymatic activities of mungbean subjected to
waterlogging. Plant Sci. 163: 117-123.
Shutenko Z, Henry Y, Pinard E, et al. 1990. Influence of antioxidant quercetin in vivo on the
level of nitric oxide determined by electron paramagnetic resonance in rat brain during
global ischemia and reperfusion. Biochem Pharmacol;57:199-208.
Van Acker SA, Tromp MN, Haenen GR, etal. 1995. Flavonoids as scavengers of nitric oxide
radical. Biochem Biophys Res Commun ;214:755-9.
Guyton dan Hall. 2004. Buku Ajar Fisiologi Kedokteran. Jakarta : EGC
Cines, D.B., Pollak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Pober, J.S.,
Wick, T.M., Konkle, B.A., Schwartz, B.S., Barnathan, E.S., McCrae, K.R., Hug,

B.A.Schmidt, A., and Stern, D.M. 1998. Endothelial Cells in Physiology of Vascular
Disorders. The Journal of The American Society of Hematology, Volume 91, No. 10.
Noer, M.S., Waspadji, S., Rachman, A.M., Lesmana, L.A., Widodo D., Isbagio, H., Alwi, I. dan
Husodo, U.B. 1996. Buku Ajar Ilmu Penyakit Dalam. Jakarta : Balai Penerbit FKUI.
Velazquez, E., Winocour, P.H., Kesteven, P., Alberti, K.G., and Laker, M.F. 1991. Relation of
lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Medicine 8, 752758.
Collier, A., Rumley, A., Rumley, A.G., Paterson, J.R., Leach, J.P., Lowe, G.D., and Small, M.
1992. Free radical activity and hemostatic factors in NIDDM patients with and without
microalbuminuria. Diabetes 41, 909-913.
MacRury, S.M., Gordon, D., Wilson, R., Bradley, H., Gemmell, C.G., Paterson, J.R., Rumley,
A.G., and MacCuish, A.C. 1993. A comparison of different methods of assessing free
radical activity in type 2 diabetes and peripheral vascular disease. Diabetic Medicine 10,
331-335.
Griesmacher, A., Kindhauser, M., Andert, S.E., Schreiner, W., Toma, C., Knoebl, P.,
Pietschmann, P., Prager, R., Schnack, C., and Schernthaner, G. 1995. Enhanced serum
levels of thiobarbituric-acid-reactive substancesin diabetes mellitus. Am. J. Med. 98,
469-475.
Santini, S.A., Marra, G., Giardina, B., Cotroneo, P., Mordente, A., Martorana, G.E., Manto, A.,
and Ghirlanda, G. 1997. Defective plasma antioxidant defenses and enhanced
susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46, 1853-1858.
Robertson, R.P. 2004. Chronic oxidative stress as a central mechanism for glucose toxicity in
pancreatic islet beta cells in diabetes, J. Biol. Chem. 279(41), 4235142354.
West, I.C., 2000. Radicals and oxidative stress in diabetes. Diabetic Med. 17, 171180.
Hiramatsu, K, S. Arimori, 1988. Increased superoxide production by mononuclear cells of
patients with hypertryglycerdemia and diabetes, Diabetes 37, 832837.
Koh, et al. 2003. Peroxisome Proliferator-Activated Receptor (PPAR)Diabetes

in

OLETF

Rats.

Activation Prevents
(Online)

(http://diabetes.diabetesjournals.org/cgi/content/full/52/9/2331?
maxtoshow=&HITS=&hits=&RESULTFORMAT=&fulltext=Diabetes+PPAR&andorexa

10

ctfulltext=and&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT,

diakses

28

September 2009)
Bastaa, G., Ann Marie Schmidtb, and Raffaele De Caterina. 2004. Advanced glycation end
products and vascular inflammation: implications for accelerated atherosclerosis in
diabetes. Cardiovascular Research, 63: 582 592
Kanthryn C.B., Tan, Wing-Sun Chow, Victor, H.G. AI, Christine Metz, Richard Bucala, and
Karen S.L. Lam. 2002. Advanced Glycation End Products and Endothelial Dysfunction
in Type 2 Diabetes. Diabetes Care, 25:10551059, 2002
Aragno, M., E. Tamagno, V. Gato, E. Brignardello, S. Parola, O. Danni, G. Boccuzzi. 1999.
Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative
stress. Free Radic. Biol. Med. 26(11/12), 14671474.
Sato, Y., Hotta, N., Sakamoto, N., Matsuoka, S., Ohishi, N., and Yagi, K. 1979. Lipid peroxide
level in the plasma of diabetic patients. Biochemical Medicine and Metabolic Biology
21(1),104-107.
Velazquez, E., Winocour, P.H., Kesteven, P., Alberti, K.G., and Laker, M.F. 1991. Relation of
lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Medicine 8, 752758.
Collier, A., Rumley, A., Rumley, A.G., Paterson, J.R., Leach, J.P., Lowe, G.D., and Small, M.
1992. Free radical activity and hemostatic factors in NIDDM patients with and without
microalbuminuria. Diabetes 41, 909-913.
MacRury, S.M., Gordon, D., Wilson, R., Bradley, H., Gemmell, C.G., Paterson, J.R., Rumley,
A.G., and MacCuish, A.C. 1993. A comparison of different methods of assessing free
radical activity in type 2 diabetes and peripheral vascular disease. Diabetic Medicine 10,
331-335.
Neri, S., Bruno, C.M., Raciti, C., Dangelo, G., Damico, R., and Cristaldi, R. 1994. Alteration of
oxide reductive and haemostatic factors in type 2 diabetics. Journal of Internal Medicine
236, 495-500.
Griesmacher, A., Kindhauser, M., Andert, S.E., Schreiner, W., Toma, C., Knoebl, P.,
Pietschmann, P., Prager, R., Schnack, C., and Schernthaner, G. 1995. Enhanced serum

11

levels of thiobarbituric-acid-reactive substancesin diabetes mellitus. Am. J. Med. 98,

469-475.
Niskanen, L.K., Salonen, J.T., Nyyssonen, K., and Uusitupa, M.I. 1995. Plasma lipid
peroxidation and hyperglycaemia: a connection through hyperinsulinaemia? Diabetic
Medicine 12, 802-808.
Santini, S.A., Marra, G., Giardina, B., Cotroneo, P., Mordente, A., Martorana, G.E., Manto, A.,
and Ghirlanda, G. 1997. Defective plasma antioxidant defenses and enhanced
susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46, 1853-1858.
Cederberg, J., Basu, S., and Eriksson, U.J. 2001. Increased rate of lipid peroxidation and protein
carbonylation in experimental diabetic pregnancy. Diabetologia 44, 766-774.
Wautier, J. L., M. P. Wautier., A.M. Schmidt., G. M. Anderson., H. Rif, C. Zoukourian., L.
Capron., Chappey, S.D., Yan, J., Breyf, P.J., Guillausseauii, and D. SterniI. 1994.
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to
the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link
between surface associated AGEs and diabetic complications. Proc. Natl. Acad. Sci, Vol.
91, pp. 7742-7746.
Robertson, R.P. 2004. Chronic oxidative stress as a central mechanism for glucose toxicity in
pancreatic islet beta cells in diabetes, J. Biol. Chem. 279(41), 4235142354.
West, I.C., 2000. Radicals and oxidative stress in diabetes. Diabetic Med. 17, 171180.
Lenzen, S., J. 1996. Drinkgern, M. Tiedge, Low antioxidant enzyme gene expression in
pancreatic islets compared with various other mouse tissues, Free Radic. Biol. Med., 20,
463466.
Lyons, T.J. 1991. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis
in diabetes? Diabet Med. 8, 411 419.
Steiner, G. 1985. Atherosclerosis, the major complication of diabetes, Adv. Exp. Med. Biol.189,
277297.
Hiramatsu, K, S. Arimori, 1988. Increased superoxide production by mononuclear cells of
patients with hypertryglycerdemia and diabetes, Diabetes 37, 832837.
Wautier, J.L. and P.J. Guillausseau. 2001. Advanced Glycation End Products, Their Receptors
and Diabetic Angiopathy. Diabetes Metab, 27: 535-542

12

Mohamed, A.K., A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, P.P. Nawroth, 1999. The
role of oxidative stress and NF-Kappa B activation in late diabetic complications,
Biofactors, 10, 157167.
Nyunai, N., Njifutie, Njikam., Catherine, M and Philippe Pastoureau. 2006. Blood Glucose
Lowering Effect of Aqueous Leaf Extracts of Ageratum conyzoides in Rats. African
Journal of Traditional, Complementary and Alternative Medicines, Vol. 3, No. 3, pp. 7679
Halliwel, B and Gutteridge, J. M. 1999. Free Radicals. In Biology and Medicine. Third Edition.
Oxford Science Publications.
Cerellio, A, N. Bortolotti, M. Pirisi, et al. 1997. Total plasma antioxidant capacity predicts
thrombosis-prone status in NIDDM patients, Diabetes Care. 20, 1589 93.
Baldwin, A. S., Jr. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights.
Annu Rev Immunol 14:649-83.
Ghosh, G., G. van Duyne, S. Ghosh, and P. B. Sigler. 1995. Structure of NF-kappa B p50
homodimer bound to a kappa B site. Nature 373:303-10.
Hayden, M. S., A. P. West, and S. Ghosh. 2006. NF-kappaB and the immune response. Oncogene
25:6758-80.
Ghosh, G., G. van Duyne, S. Ghosh, and P. B. Sigler. 1995. Structure of NF-kappa B p50
homodimer bound to a kappa B site. Nature 373:303-10.
Cramer, P., C. J. Larson, G. L. Verdine, and C. W. Muller. 1997. Structure of the human NFkappaB p52 homodimer-DNA complex at 2.1 A resolution. Embo J 16:7078-90.
Malek, S., Y. Chen, T. Huxford, and G. Ghosh. 2001. IkappaBbeta, but not IkappaBalpha,
functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NFkappaB nuclear localization sequences in resting cells. J Biol Chem 276:45225-35.
Courtois, G., and T. D. Gilmore. 2006. Mutations in the NF-kappaB signaling pathway:
implications for human disease. Oncogene 25:6831-43.
Pahl, H. L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene
18:6853-66.
Weil, R., S. T. Whiteside, and A. Israel. 1997. Control of NF-kappa B activity by the I
kappa B beta inhibitor. Immunobiology 198:14-23.

13

Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their
role in innate and adaptive immunity. Trends Immunol 25:280-8.
Dejardin, E. 2006. The alternative NF-[kappa]B pathway from biochemistry to biology:
Pitfalls and promises for future drug development. Biochemical Pharmacology 72:11611179.
Hoffmann, A., G. Natoli, and G. Ghosh. 2006. Transcriptional regulation via the NFkappaB
signaling module. Oncogene 25:6706-16.
Boulanger CM, Vanhoute PM. The endothelium: a pivotal role in health and cardiovascular
disease. Servier International. France, 1994
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology,
pathophysiology, and management. JAMA, 287:2570-81, 2002
Creager MA, Luscher TF, Consentino F, Beckman JA. Diabetes and vascular disease.
Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation.
108:1527-32, 2003
Mc Veigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium dependent and
independent vasodelation in patient with type-2 diabetes mellitus. Diabetologia. 35:77176, 1992
Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium dependent
vasodilation impaired by acute hyperglycemia in humans. Circulation. 103:1618-23,
2001
Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes
mellitus. Circ Res. 88:E14-E22.,2001
Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. High glucose
concentration increase endothelial cell permeability via activation of protein kinase-C
alpha. Circulation Res. 81:363-71, 1997
Esper, R., Vilario, J., Machado, R., and Paragano A. 2008. Endothelial Dysfunction in Normal
and Abnormal Glucose Metabolism. Adv Cardiol. Basel, Karger, vol. 45, pp 17-43

14

Sofia, D. 2003. Antioksidan dan Radikal Bebas. (Online) (http://www.chem-is-try.org/?

sect=artikel&ext=81, diakses 23 November 2009)
Wijaya, L. dan Suyatna, F. D. 2005. Terapi Antioksidan Pada Aterosklerosis. Dexa Media, Vol.18
No.

3.

(Online)

(http://www.dexa-medica.com/

dexa/article_files/tinjauan_pustaka_02.pdf?
PHPSESSID=aa6bef47eacd6e9abe376fbcb3631cba, diakses 16 September 2009)
Moncada S, Higgs A. The L-arginine nitric oxide pathway. N Eng J Med. 329:2002-12, 1993
Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium dependent
vasodilation impaired by acute hyperglycemia in humans. Circulation. 103:1618-23,
2001
Jakus, V and N. Rietbrock. 2004. Advanced Glycation End-Products and the Progress of
Diabetic Vascular Complications. Physiol. Res. 53: 131-142
Bahorun T, Soobrattee MA, Luximon-Ramma V, Aruoma OI.2006. Free Radicals and
Antioxidants in Cardiovascular Health and Disease. Internet Journal of Medical Update
2006 Jul-Dec;1(2): http://www.geocities.com/agnihotrimed/pap er05_jul-dec2006.htm
Ares JJ, Outt PE.1998. Gastroprotective agents for the prevention of NSAID- induced
gastropathy. Curr Pharm;4:7-36.
Kerry NL, Abbey M. 1997. Red wine and fractionated phenolic compounds prepared from red
wine inhibits low density lipoprotein oxidation in vitro. Atherosclerosis ;135:93-102.
Shutenko Z, Henry Y, Pinard E, et al. 1990. Influence of antioxidant quercetin in vivo on the
level of nitric oxide determined by electron paramagnetic resonance in rat brain during
global ischemia and reperfusion. Biochem Pharmacol;57:199-208.
Van Acker SA, Tromp MN, Haenen GR, etal. 1995. Flavonoids as scavengers of nitric oxide
radical. Biochem Biophys Res Commun ;214:755-9.
Friesenecker B, Tsai AG, Allegra C, Intaglietta M. 1994. Oral administration of purified
micronized flavonoid fraction suppresses leukocyte adhesion in ischemia reperfusion
injury: in vivo observation in the hamster skin fold. Int J microcir clin Exp; 14:50-5.
Jones, Gareth E. 1996. Human Cell Culture Protocols. New Jersey : Humana Press.

15

Wajant H, Henkler F, Scheurich P. 2001. The TNF-receptor-associated factor family: scaffold

molecules for cytokine receptors, kinases and their regulators. Cell. Signal.;13:389-400.
Calamia KT. 2003. Current and future use of anti-TNF agents in the treatment of autoimmune,
inflammatory disorders. Adv. Exp. Med. Biol ;528:545-9.
Lawrence, G. S. 2004. Implikasi Klinis Disfungsi Endotel dan Radikal Bebas. (Online)
(http://med.unhas.ac.id/en//index2.php%3Foption%3Dcom_ content%26do_pdf, diakses
24 September 2009)
Taylor PC, Williams RO, Feldmann M. 2004. Tumour necrosis factor alpha as a therapeutic
target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol.;15:557-63.
Manach C, Donavan J. 2004. Pharmacokinetics and metabolism of Dietary Flavonoids in
humans. Free Radical Research;38:771-785.
Taussig SJ. 1980. The mechanism of the physiological action of bromelain. Medical
Hypothesis;6:99-104.
Ako H, Cheung AHS, Matsuura PK. 1981. Isolation of a fibrinolysis activator from commercial
bromelain. Arch. Int. Pharmacodyn.;284:157-67.
Murota K, Terao J. 2003. Antioxidative Flavonoid quercetin: Implication of its intestinal
absorption and metabolism. Arch Biochem Biophys;417:12-17.
Lesser S, Cermak R, Wolffram S. 2004. Bioavailability of quercetin in pigs is influenced by the
dietary fat content. J Nutr. Jun;134(6):1508-11.
Young JF, Nielsen SE, Haraldsdottir J, et al. 1999. Effect of fruit juice intake on urinary
quercetin excretion and biomarkers of antioxidative status. Am J Clin Nutr;69:87-94.
Formica JV, Regelson W. 1995. Review of the biology of quercetin and related bioflavonoid.
Food Chem Toxicol;33:106180.
Okamoto T. 2005. Safety of quercetin for clinical application (Review). Int J Mol Med.
Aug;16(2):275-8.
Miniscalco A, Lundahl J, Regardh CG. 1992. Inhibition of dihydropyridine metabolism in rat
and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp
Ther;261:1195-9.
Wang Y-H, Chao P-D L, Hsiu S-L, et al: 2004. Lethal quercetin-digoxin interaction in pigs. Life
Sci;74:1191-7.

16

Kempuraj D, Castellani ML, Petrarca C, et al. 2006. Inhibitory effect of quercetin on tryptase
and interleukin-6 release, and histidine decarboxylase mRNA transcription by human
mast cell-1 cell line. Clin Exp Med. Dec;6(4):150-6.
Kim HP, Mani I, Iversen L, Ziboh VA. 1998. Effects of naturally-occurring flavonoids and
bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs.
Prostaglandins Leukot Essent Fatty Acids;58:1724.
Hertog MG, Kromhout D, Aravanis C, et al. 1995. Flavonoid intake and long-term risk of
coronary heart disease and cancer in the seven countries study. Arch Intern
Med;155:3816.
Arai Y, Watanabe S, Kimira M, et al. 2000. Dietary intakes of flavonols, flavones and isoflavones
by Japanese women and the inverse correlation between quercetin intake and plasma
LDL cholesterol concentration. J Nutr;130:224350.
Hegarty VM, May HM, Khaw KT. 2000. Tea drinking and bone mineral density in older women.
Am J Clin Nutr;71:10037.
Chang WS, Lee YJ, Leu FJ, Chiang HC. 1993. Inhibitory effects of Flavonoids on xanthine
oxidase. Anticancer Res;13:2165-70.
Cai J, Nelson KC, Wu M, et al. 2000. Oxidative damage and protection of the RPE. Prog Retin
Eye Res.;19(2):205-21.
Singh A, Naidu PS, Kulkarni SK. 2003. Reversal of aging and chronic ethanol induced
cognitive dysfunction by quercetin.a bioflavonoid. Free Radic Res;37(11):12
Heo HJ, Kim DO, Choi SJ, et al. 2004. Apple Phenolics Protect in Vitro Oxidative Stressinduced
Neuronal Cell Death. J Food Sci;69(9):S357-60.
Costantino L, Rastelli G, Gamberini MC, et al. 1999. 1-Benzopyran -4-one antioxidant as aldose
reductase inhibitors. Med Chem;42:1881-93.
Muhammad A, Soobrattee, Bahorun T, Okezie I Aruoma. 2006. Chemopreventive actions of
plyphenolic compounds in cancer. BioFactors;27:19-35.
Alarcon de La Lastra C, Martin MJ, Motilve V. 1994. Antiulcer and gastroprotective effects of
quercetin: a gross and histological study.Pharmacol.;48:56-62.
.
Lampiran 1

17

BIODATA ANGGOTA KELOMPOK

1. Biodata Anggota Kelompok 1

Nama
: Gamal
NIM
: 0710713014
Jurusan / Angkatan : Pendidikan Dokter FKUB/ 2007
Alamat
: Jl. Ahmad Yani No.129, Malang
Nomer HP
: 08179602820
Alamat e-mail
: dr_helper77@yahoo.com
Prestasi
:
Karya Tulis yang Pernah dibuat:
a. Akibat kebijaksanaan pemerintah terkait cukai rokok yang berimbas pada
kesehatan masyarakat
b. Pengaruh waktu malam hari terhadap munculnya penyakit asma
c. Pengaruh perubahan status rumah sakit menjadi Badan Layanan Umum
(BLU)
d. Analisis Potensi Ekstrak Caricca Papaya L, sebagai salah satu alternatif alat
kontrasepsi pada pria
e. Uji Potensi Quercetin dalam ekstrak kulit buah apel (Pyrus Malus) terhadap
Ekspresi NF-kB Human Umbilical Vein Endothelial Cell (HUVECs) In Vitro
kondisi glukosa tinggi : Sebagai Pendekatan terapi Komplikasi Vaskuler
Diabetes Melitus Tipe II
f. Analisis Potensi Quercetin terhadap aktivasi NF-kB dan Telomere Shortening:
Upaya Strategis mencegah Premature Aging pada penderita DM tipe II
2. Biodata Anggota Kelompok 2
Nama
: Hamid Hunaif Dhofi
NIM
: 0710710076
Jurusan / Angkatan : Pendidikan Dokter FKUB/ 2007
Alamat
: Jalan Pasar Sukerejo 22 Pasuruan jawa Timur
Nomer HP
: 085 655 555 054
Alamat e-mail
: dhodo_dhofi@yahoo.com
Prestasi
:
a. Peraih penghargaan setara emas pada PIMNAS XXIII tahun 2009 di
UB pada bidang penelitian.
b. Juara Harapan 1 Lomba Desain Poster Ilmiah tingkat Nasional tahun
2008 pada Scientific Atmosphere, Bali.
c. Juara 2 Lomba Desain Esai dalam Poster tingkat Malang tahun 2008
pada Pekan Sains Islami.

18

d. Juara 3 Lomba Desain Poster tahun 2008 Dies Natalis Universitas

Brawijaya.
Karya Tulis yang Pernah dibuat:
a. Efek Ekstrak Kulit Kayu Durian pada Ekspresi iNOS pada Model Tikus
Putih Artritis Ajuvant.
b. Efek Kulit Jeruk Purut pada Kolonisasi Salmonella typhimurium secara
in vitro.
c. Jeruk Bali sebagai Terapi Alternatif Antioksidan untuk Perokok Aktif
dan Pasif.